Southern Jo, Borrow Ray, Andrews Nick, Morris Rhonwen, Waight Pauline, Hudson Michael, Balmer Paul, Findlow Helen, Findlow Jamie, Miller Elizabeth
Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom.
Clin Vaccine Immunol. 2009 Feb;16(2):194-9. doi: 10.1128/CVI.00420-08. Epub 2008 Dec 17.
This study investigated the use of two doses of three different meningococcal group C conjugate (MCC) vaccines when given for primary immunization with a seven-valent pneumococcal conjugate vaccine (PCV7) and Pediacel, a combination product containing five acellular pertussis components, diphtheria and tetanus toxoids, Haemophilus influenzae type b (Hib) conjugate, and inactivated-poliovirus vaccine. The immune response after a single dose of MCC is also presented. Infants were randomized to receive two doses of one of the MCC vaccines and PCV7 at 2 and 3 months or at 2 and 4 months of age. Meningococcal group C serum bactericidal antibody (SBA) geometric mean titers, Hib-polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) geometric mean concentrations (GMCs), and diphtheria and tetanus antitoxin GMCs, together with the proportions of infants achieving putative protective levels, were determined. A total of 393 infants were recruited. Following the first dose of NeisVac-C (MCC conjugated to tetanus toxoid), 97% of infants achieved protective levels (SBA titer of >or=8), compared with 80% and 53%, respectively, for Menjugate and Meningitec (both of which are conjugated to CRM(197)). SBA responses to MCC vaccines were not significantly different when administered at 2 and 3 or 2 and 4 months of age. Following two doses of each MCC, 98 to 100% of infants achieved protective levels. Both PRP IgG and tetanus responses were significantly enhanced when Pediacel was coadministered with NeisVac-C. This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies.
本研究调查了两种剂量的三种不同的C群脑膜炎球菌结合疫苗（MCC）与七价肺炎球菌结合疫苗（PCV7）和Pediacel联合用于初次免疫时的情况。Pediacel是一种联合产品，包含五种无细胞百日咳成分、白喉和破伤风类毒素、b型流感嗜血杆菌（Hib）结合疫苗以及灭活脊髓灰质炎疫苗。本文还介绍了单剂量MCC后的免疫反应。婴儿被随机分为两组，分别在2个月和3个月龄或2个月和4个月龄时接受两剂MCC疫苗之一和PCV7。测定了C群脑膜炎球菌血清杀菌抗体（SBA）几何平均滴度、Hib - 多聚核糖磷酸（PRP）免疫球蛋白G（IgG）几何平均浓度（GMC）、白喉和破伤风抗毒素GMC，以及达到假定保护水平的婴儿比例。共招募了393名婴儿。接种第一剂NeisVac - C（与破伤风类毒素结合的MCC）后，97%的婴儿达到保护水平（SBA滴度≥8），而Menjugate和Meningitec（两者均与CRM(197)结合）的这一比例分别为80%和53%。在婴儿2个月和3个月龄或2个月和4个月龄时接种MCC疫苗，其SBA反应无显著差异。接种两剂每种MCC后，98%至100%的婴儿达到保护水平。当Pediacel与NeisVac - C联合接种时，PRP IgG和破伤风反应均显著增强。本研究表明，NeisVac - C和Menjugate在2个月龄时与PCV7和Pediacel联合接种第一剂后具有良好的免疫原性，值得对单剂量启动策略进行进一步研究。
